UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 12, 2021 idxx-20210512_g1.jpg

	ID	EXX LABORA	ATORIES,	INC.					
(Exact name of registrant as specified in its charter)									
	Delaware (State or other jurisdiction of incorporation)	000-19271 (Commission File Number)		01-0393723 (IRS Employer Identification No.)					
	One IDEXX Drive (Address of prir	Westbrook, acipal executive offices)	Maine	04092 (ZIP Code)					
207.556.0300 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)									
Check the appropri		ded to simultaneously satisfy th	ne filing obligation of the	ne registrant under any of the following provisions (see General					
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)								
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)								
	☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))								
	☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))								
Securities registered pursuant to Section 12(b) of the Act:									
Common	Title of each class Stock, \$0.10 par value per share	Trading Symbol	<u>(s)</u>	NASDAQ Global Select Market					
	mark whether the registrant is an emerging ities Exchange Act of 1934 (ß240.12b-2 of			5 of the Securities Act of 1933 (ß230.405 of this chapter) or Rule					
If an emerging grow	wth company, indicate by check mark if the	registrant has elected not to us	se the extended trans	ition period for complying with any new or revised financial					

accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

D7. Submission of Matters to a Vote of Security Holders.

On May 12, 2021, IDEXX Laboratories, Inc. (the "Company") held its 2021 annual meeting of shareholders (the "Annua Meeting"). At the Annual Meeting, shareholders considered and voted on the following proposals, each of which is described in more detail in the Company's proxy statement dated March 31, 2021, (the "Proxy Statement"): (1) the election of Daniel M. Junius as a Class II director, for a term that expires at the 2023 annual meeting of shareholders, and Bruce L. Claflin, Asha S. Collins, PhD and Sam Samad each as Class I directors, for terms expiring at the 2024 annual meeting of shareholders; (2) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the current fiscal year; and (3) the approval, on an advisory basis, of the compensation of the Company's named executive officers as presented in the Proxy Statement delivered to shareholders in connection with the Annual Meeting.

The voting results at the Annual Meeting with respect to each of the matters described above, were as follows:

Nominees	For	Against	Abstain	Broker Non-Votes
Bruce L. Claflin	67,436,772	2,861,273	60,122	6,378,832
Asha S. Collins, PhD	67,802,484	2,502,566	53,117	6,378,832
Daniel M. Junius	69,481,500	822,362	54,305	6,378,832
Sam Samad	69,493,423	809,390	55,354	6,378,832

Proposal Two:	Ratification of Appointment of Independent Registered Public Accounting Firm		
For	74,352,030		
Against	2,342,427		
Abstain	42,542		
Broker Non-Votes	N/A		

Proposal Three:	Advisory Vote to Approve Executive Compensation	
For		66,390,797
Against		3,860,320
Abstain		107,050
Broker Non-Votes		6,378,832

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEXX LABORATORIES, INC.

Date: May 18, 2021 /s/ Sharon E. Underberg By:

Sharon E. Underberg

Senior Vice President, General Counsel and Corporate Secretary